Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$438.17 0.00 (0.00)%
Market Cap 45.74B
09/20/17 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Sep 16, 2017
Bank of America Merrill Lynch Global Healthcare Conference
Sep 13, 2017 | 5:40 AM ET